Savant Capital LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Savant Capital LLC boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 57.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,738 shares of the biopharmaceutical company's stock after purchasing an additional 4,291 shares during the quarter. Savant Capital LLC's holdings in Alnylam Pharmaceuticals were worth $2,762,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in ALNY. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $33,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $42,000. Finally, True Wealth Design LLC boosted its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 153 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the business's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the transaction, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 73,964 shares of company stock worth $20,622,925 over the last quarter. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Down 3.2 %

Alnylam Pharmaceuticals stock traded down $8.44 during mid-day trading on Friday, hitting $256.45. The company had a trading volume of 805,993 shares, compared to its average volume of 695,622. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock's 50 day moving average price is $254.03 and its two-hundred day moving average price is $263.53. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market capitalization of $33.08 billion, a PE ratio of -97.88 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ALNY. Needham & Company LLC reiterated a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Barclays lifted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. TD Cowen raised their price objective on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a report on Monday, October 21st. Piper Sandler reissued an "overweight" rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Wolfe Research cut Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $299.43.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.